Conversely, a MOR agonist with bias for G-protein signaling over βarrestin2 recruitment provides a lower level of respiratory depression for a given level of analgesia, and is a strategy for developing safer opioids (Schmid et al., 2017; Viscusi, 2019). This evidence concerns the gene OPRM1 and Respiratory insufficiency due to muscle weakness.